DTIL, US74019P2074

Director bought 1,135 shares of Precision BioSciences stock

Published on 10/07/2026 at 01:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For Precision BioSciences stock this means USD 112.0 million in cash. The company dosed 16 patients in 38 administrations.

DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences, Inc. (ISIN US74019P2074) director Melinda Brown purchased 1,135 shares for USD 7,116 on September 25, 2026, according to Investing.com. The transaction gives the director direct ownership of 45,481 shares, while Precision continues developing two clinical gene-editing programs.

Insider purchase meets clinical progress

Brown paid USD 6.27 per share in the transaction, which took place on September 25, 2026. The purchase followed a period in which the stock had declined 13 percent over the previous week, according to Investing.com.

Precision presented PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy at the H.C. Wainwright conference on September 16, 2026, as reported by Investing.com. The company said 16 patients had received 38 administrations in the hepatitis B program, while the DMD program began dosing in August 2026.

Cash runway shapes the story

Precision reported USD 112.0 million in cash and cash equivalents at the end of the second quarter of 2026 and said that balance supports a runway through 2028, according to Investing.com. That financing window gives the two programs time to produce additional clinical data, but both remain in early-stage testing.

The next milestones are safety data for PBGENE-DMD by the end of 2026 and biopsy data in 2027. For PBGENE-HBV, management expects another data update before the end of 2026, with the American Association for the Study of Liver Diseases conference in November identified as a possible venue.

Analyst view stays divided

MarketBeat reported on September 17, 2026, that four of five covering brokerages rated Precision BioSciences a Buy and one rated it Sell. The average 12-month price target was USD 32.25, while Oppenheimer had initiated coverage with an Outperform rating and a USD 20.00 target, according to MarketBeat. The wide spread between clinical-stage milestones and current earnings risk keeps the analyst picture conditional rather than uniform.

Stock reference remains EUR 5.51

The prior close at Lang & Schwarz was EUR 5.51 on October 5, 2026. Precision BioSciences is listed on Nasdaq under DTIL, and its market capitalization was USD 171.1 million on October 6, 2026.

The further course of trading is shown by the continuously updated real-time quote of Precision BioSciences stock.